<?xml version="1.0"?>
<Articles JournalTitle="Basic &amp; Clinical Cancer Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Basic &amp; Clinical Cancer Research</JournalTitle>
      <Issn>2228-6527</Issn>
      <Volume>13</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>08</Month>
        <Day>31</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Cardio-Oncology in Iran: Cardio-toxicity Registry</title>
    <FirstPage>235</FirstPage>
    <LastPage>238</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Azin</FirstName>
        <LastName>Alizadehasl</LastName>
        <affiliation locale="en_US">Shaheed Rajaie Cardiovascular Medical &amp; Research Center, Cardio-Oncology Research Center, Iran University of Medical Science, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Niloufar</FirstName>
        <LastName>Akbari Parsa</LastName>
        <affiliation locale="en_US">Dr. Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Feridoun</FirstName>
        <LastName>Noohi</LastName>
        <affiliation locale="en_US">Shaheed Rajaie Cardiovascular Medical &amp; Research Center, Iran University of Medical Science, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Reza</FirstName>
        <LastName>Golpira</LastName>
        <affiliation locale="en_US">Shaheed Rajaie Cardiovascular Medical &amp; Research Center, Iran University of Medical Science, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Amir</FirstName>
        <LastName>Abdi</LastName>
        <affiliation locale="en_US">Islamic Asad Univeristy, Tehran Medical Branch, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Amir Hossein</FirstName>
        <LastName>Emami</LastName>
        <affiliation locale="en_US">Emam Khomeni Hispital, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Asadollah</FirstName>
        <LastName>Moosavi</LastName>
        <affiliation locale="en_US">Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ghasem</FirstName>
        <LastName>Janbabaei</LastName>
        <affiliation locale="en_US">Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>07</Month>
        <Day>24</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Advances in cancer treatment have resulted in a growing number of cancer survivors.However, powerful treatments such as chemotherapy, radiation treatments, and&#xA0;some cancer drugs are not without risks, including the potential for serious, long-term&#xA0;damage to the heart. Cardiology and oncology specialists often collaborate to mitigate&#xA0;these risks when treating cancer patients. This joining is known as cardio-oncology.
The main goals of cardio-oncology are to screen for and actively manage modifiable&#xA0;cardiovascular risk factors and diseases in cancer patients. Cardio-oncology plays an&#xA0;increasingly active role at every stage of cancer therapy, including baseline risk assessment&#xA0;pretreatment, surveillance and prevention during treatment, response to acute&#xA0;complications, and assessment of survivors&#x2019; post-cardiotoxic treatments. Cancer treatment
has been optimized through new treatment strategies. The first cardio-oncology&#xA0;clinic in Iran was instituted about 4 years ago (2017) at Shaheed Rajaei Cardiovascular&#xA0;Medical and Research Center in Tehran, which is the first cardio-oncology clinic in&#xA0;the Middle East. It provides care for cancer patients with a history of cardiovascular&#xA0;disease or risk for cardiotoxicity during cancer therapy. Also, all patients are enrolled
in the multicenter cardio-oncology Toxicity Registry research database, and 13 other&#xA0;hospitals from different centers in the whole country are involved in the registry. The&#xA0;establishment of the cardio-oncology clinic with a focus on the patient registry is discussed&#xA0;in this article.</abstract>
    <web_url>https://bccr.tums.ac.ir/index.php/bccrj/article/view/428</web_url>
  </Article>
</Articles>
